Daiichi Sankyo, Maruishi eye generic Remifentanil; Mindray board appoints committee on buyout proposal;

> Japan's Daiichi Sankyo and Maruishi Pharmaceutical will work to commercialize a generic version of Remifentanil as an opioid analgesic injection, for which Maruishi Pharmaceutical is currently applying for a manufacturing and marketing license. Release

> Australia's Novogen ($NVGN) Chairman Graham Kelly on June 24 said that "with $45M in cash, and the very real prospect of another $33M by the end of the year via short-term warrants, our shareholders have given the company the opportunity it asked for to prove the merit of its two technology platforms" with chemotherapy drug Ansina set to enter the clinic in 2016. Release (PDF)

> DKSH Business Unit Healthcare will provide marketing, sales and distribution and logistics services for Omron Healthcare, a leading manufacturer and distributor of personal wellness products from Japan in Malaysia and Thailand, extending an effort already underway in Vietnam. Release

> Singapore's Institute of Microelectronics and local diagnostics firm INEX Innovations Exchange aim to develop a non-invasive prenatal diagnostic technology. Report

> China will increase product recalls for ordinary consumer products in an effort to enhance consumer safety, under a draft regulation put forward by the country's quality watchdog, the General Administration of Quality Supervision, Inspection and Quarantine. Report

> Taiwan's National Health Research Institute released research that shows people who take proton pump inhibitors, a common drug used to treat gastroesophageal reflux and gastric ulcers face a fivefold risk of experiencing gastrointestinal infections, including salmonella. Report

> Australia's CSL Behring said Phase III data supported the use of its investigational long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP) for routine prophylaxis. Release

> Japan's Pharmaceuticals and Medical Devices Agency (PMDA) will hold its 6th training seminar for international regulatory authorities Oct. 19 to 23, focused on post-marketing safety measures. Release

> The board of China's Mindray Medical International ($MR) has formed a special committee of three independent directors to consider the previously announced non-binding senior management buyout proposal. Release

> India's Tech Mahindra has set up a healthcare-focused IT outsourcing service called "nth dimension," the company told Reuters. Report

> A Stanford University-based Japanese researcher, Hiromitsu Nakauchi, will aim to produce human organs in pigs using induced pluripotent stem cells in experiments slated to start in August, the Nikkei Asian Review said. Report

> China's FDA this month formally joined the international coalition provisional stage drug regulatory agency management committee. Release (Chinese language)

> India plans to open to the public a database on domestic drug manufacturing quality checks following concerns over spurious drugs emanating from the country. Report

> Japan's Eisai signed a deal for consulting firm Accenture to provide information technology (IT) system maintenance and operations in the U.S. and Japan. Release

> France-based Vaxon Biotech said it has been granted a new patent in Japan covering a series of optimized cryptic peptides to be used in the design of the Vbx-026, a new cancer vaccine for solid tumors. Report

> The Indian unit of GSK announced the appointment of Annaswamy Vaidheesh, as vice president, South Asia & managing director effective Aug. 3, to succeed Hasit Joshipura. Release (PDF)

> Takeda Pharmaceutical said that François-Xavier Roger has resigned as CFO to take a similar job with Nestlé. Release

> India's Cadila Healthcare says its Zydus unit has won final U.S. FDA approval for pyridostigmine bromide tablets. Release (PDF)